Classification of genetic variants of the genes BRCA1 and BRCA2 is an ongoing process. About 14% of all variants that are found in these genes are variants of unclassified significance (VUS, Class 3, uncertain) as reported earlier [1]. The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) updates the classification of all genetic variants in close cooperation with the ENIGMA Consortium (Evidence-based Network for the Interpretation of Germline Mutant Alleles), which bases its classification on the ACMG guidelines [2]. This work is done by a panel of experts. According to Plon et al., variants are classified into Classes 1–5 with Class 1 being benign without any clinical relevance and Class 5 being a pathogenic mutation [3]. In our work, on genetic BRCA1/2 variants in the Centre of Dresden, we listed VUS Class 3 (uncertain) for BRCA1 and for BRCA2, but due to the ongoing classification process, some of them are currently classified differently. In all of the cases, the variants were down-staged to less important variants of Class 2 (likely benign) or Class 1 (benign). In BRCA1 25% of the Class 3 variants (n = 2/8) changed to Class 2 (likely benign) and Class 1 (benign). In BRCA2, in 50% of the Class 3 variants (n = 16/32), a change to Class 2 (n = 10/16) or Class 1 (n = 6/16) was observed. No change in classification was noted in Class 4 (likely pathogenic) and Class 5 (pathogenic) genetic variants in both genes. No up-staging from Class 1, Class 2 or Class 3 to more clinical significance was observed. Altogether, in BRCA1, 16 index patients and, in BRCA2, 57 index patients were affected by the change in classification. Instead of the initially reported VUS rate of 14%, we now report a VUS rate of 6%. The changes are the following: BRCA1: c.591C>T, Class 2; c.1486C>T, Class 1; BRCA2: c.5199C>T, Class 2; c.4068G>A, Class 2; c.10095delCins11, Class 2; c.7347T>C, Class 2; c.6322C>T, Class 1; c.3516G>A, Class 2; c.68-7T>A, Class 2; c.6540G>C, Class 2; c.4054G>T, Class 2; c.7017G>C, Class 1; c.10234A>G, Class 1; c.9730G>A, Class 1; c.198A>G, Class 2; c.1395A>C, Class 2; c.3264T>C, Class 1; c.5418A>G, Class 1; c.8694G>A, Class 2; c.10110G>A, Class 2. The GC-HBOC informs all its centres via a recall system on revisions in the classification of genetic variants in its joint database [5]. Based on the changes from Class 3 to Class 2 or Class 1, no modification of clinical recommendations is needed. Since most VUS Class 3 will result in benign effects, intensified screening is only justified in families with high risks according to pedigree-based calculation models as Cyrillic or BOADICEA [2]. This is also the case in families without any abnormal finding in the molecular analysis of the breast and ovarian cancer genes. Because of lacking clinical consequences, some have already suggested not to disclose the result of a Class 3 variant to patients [4]. However, segregation analysis on research basis, where appropriate according to pedigree information, is an important aspect for the classification of variants and collection of blood from other family members would not be possible without basic information about the VUS. For good clinical practice, it is important to state that intensified surveillance or prophylactic operations are not justified by VUS. Patients with analysis results with VUS outside the GC-HBOC are recommended to contact their geneticist for an update on classification after a few years.